 CRANBURY, N.J., Jan. 7, 2022 PRNewswire -- Palatin Technologies, Inc. NYSE American: PTN, a specialized biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin peptide receptor system, announced that the Company will present and host one-on-one meetings at the H.C. 